Biofrontera AG
BIFRF
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -62.52% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -62.51% | -- |
| Cost of Revenue | -- | -- | -- | -78.59% | -- |
| Gross Profit | -- | -- | -- | -58.33% | -- |
| SG&A Expenses | -- | -- | -- | -24.50% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -56.50% | -- |
| Operating Income | -- | -- | -- | -101.56% | -- |
| Income Before Tax | -- | -- | -- | 198.99% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | 1,039.78% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -339.13% | -- |
| EBIT | -- | -- | -- | -101.56% | -- |
| EBITDA | -- | -- | -- | -93.63% | -- |
| EPS Basic | -- | -- | -- | 90.86% | -- |
| Normalized Basic EPS | -- | -- | -- | 95.51% | -- |
| EPS Diluted | -- | -- | -- | 90.90% | -- |
| Normalized Diluted EPS | -- | -- | -- | 95.51% | -- |
| Average Basic Shares Outstanding | -- | -- | -- | 128.42% | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | 128.42% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |